P01-050 – Anakinra in systemic JIA: single center experience
نویسندگان
چکیده
Introduction Systemic juvenile idiopathic arthritis (sJIA) accounts for 10-20% of all patients with JIA. The clinical features include fever, evanescent rash, arthralgia and arthritis, myalgia, lymphadenopathy, hepatomegaly, splenomegaly and serositis. Interleukin 1 (IL-1) has been shown to be a major mediator of the inflammatory cascade that underlies sJIA (1). Treatment with anakinra, IL-1 receptor antagonist has been reported to be effective in a subset of patients with sJIA (2)
منابع مشابه
Experience of one UK site presenting a closer examination of safety and efficacy of Anakinra (Kineret®) in systemic juvenile idiopathic arthritis
Methods 10 patients (3–17 yrs) with sJIA were enrolled onto a 12 week study at our institution. All patients fulfilled the ILAR classification for sJIA. Out of the 10 patients, 9 had failed anti-TNF. All patients received Anakinra at 2 mg/kg/ day subcutaneously with their current therapy, except anti-TNF. Responders met Definition of Improvement (DOI) criteria by >30% improvement in at least 3 ...
متن کاملAkinra restores the defective IL-18 NK cell axis in steroid naïve systemic onset JIA patients
Systemic Onset Juvenile Idiopathic Arthritis (SoJIA) is characterized by systemic inflammation and chronic arthritis. Intriguingly, the IL-18-NK cell axis seems to be disturbed in the majority of SoJIA patients. The observed NK cell dysfunction in SoJIA patients contributes to important features of the disease including the susceptibility for macrophage activation syndrome. Here we describe the...
متن کاملAnakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.
OBJECTIVE To examine the safety and efficacy of the interleukin-1 (IL-1) receptor antagonist anakinra as first-line therapy for systemic juvenile idiopathic arthritis (JIA). METHODS Patients with systemic JIA receiving anakinra as part of initial disease-modifying antirheumatic drug (DMARD) therapy were identified from 11 centers in 4 countries. Medical records were abstracted using a standar...
متن کاملInflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis
BACKGROUND Inflammatory bowel disease can develop in the context of some rheumatic diseases in childhood, including juvenile idiopathic arthritis (JIA). Inflammatory bowel disease (IBD) is frequently associated with other immune-mediated diseases; however, systemic onset JIA (sJIA) has not previously been connected to IBD. Treatment of sJIA has significantly changed in recent years, possibly ca...
متن کاملEarly effects of Anakinra in corticosteroid naïve SOJIA patients
Interleukin-1R antagonist (anakinra) induces disease remission in about 50% of corticosteroid (CS) resistant cases of systemic onset JIA (SOJIA) [1,2]. Clinicians debate whether etanercept should still be tried first before giving anakinra to such patients. Another, more chalenging, issue is to start anakinra even in CS naïve SOJIA patients. We here report our first experiences of such an appro...
متن کامل